CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management of autosomal domInAnt poLycystic kidney disease (ESSENTIAL): short-term outcomes during the titration period
Hyuk Huh, Yong Soo Kim, Wookyung Chung, Yong Lim Kim, Yaerim Kim, Seungyeup Han, Yeonsoon Jung, Ki Young Na, Kyu Beck Lee, Yun Kyu Oh, Hyeong Cheon Park, Seung Hyeok Han, Tae Hyun Yoo, Yeong Hoon Kim, Soo Wan Kim, Kang Wook Lee, Hayne Cho Park, Sung Gyun Kim, Hyunsuk Kim, Chang Hwa Lee, Kyongtae T. Bae, Kook Hwan Oh, Curie Ahn, Hyun Jin Ryu, Yong Chul Kim
Kidney Res Clin Pract. 2023;42(2):216-228.   Published online January 13, 2023
DOI: https://doi.org/10.23876/j.krcp.22.024

Excel Download

Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management of autosomal domInAnt poLycystic kidney disease (ESSENTIAL): short-term outcomes during the titration period
Kidney Research and Clinical Practice. 2023;42(2):216-228   Crossref logo
Link1 Link2 Link3

Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
Therapeutics and Clinical Risk Management. 2021;Volume 17:649-656   Crossref logo
Link1 Link2

Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial
Drug, Healthcare and Patient Safety. 2017;Volume 9:93-104   Crossref logo
Link1 Link2

Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial [Corrigendum]
Drug, Healthcare and Patient Safety. 2018;Volume 10:67-68   Crossref logo
Link1 Link2

MO025: Long-term follow-up of patients with autosomal dominant polycystic kidney disease treated with tolvaptan
Nephrology Dialysis Transplantation. 2022;37(Supplement_3):   Crossref logo
Link1 Link2

Short-term changes in micturition patterns with tolvaptan treatment for autosomal dominant polycystic kidney disease
Asian Journal of Surgery. 2021;44(10):1332-1333   Crossref logo
Link1 Link2

MO031: Long-term safety of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease
Nephrology Dialysis Transplantation. 2022;37(Supplement_3):   Crossref logo
Link1 Link2

Commentary on: Tolvaptan in Patients With Autosomal-Dominant Polycystic Kidney Disease
Urology. 2013;81(4):705-706   Crossref logo
Link1 Link2

Tolvaptan
Reactions Weekly. 2022;1914(1):410-410   Crossref logo
Link1 Link2 Link3

Magnetic resonance imaging is effective for evaluating the therapeutic effect of tolvaptan on total kidney volume in patients with autosomal dominant polycystic kidney disease
Renal Replacement Therapy. 2018;4(1):   Crossref logo
Link1 Link2 Link3